Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 6
CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 6